Fig. 2From: Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseasesCount of FDA orphan drug designations and total approvals by year, 1983–2019Back to article page